Return to Today's science sparks archives

2012-01-03

Fig 5. Immunohistochemistry staining of tissues with 19E3 anti-CAR Ab. (A) Trafficking of targeted T cells to tumor sites in CLL-4 44 hours after T-cell infusion.

Fig 5. Immunohistochemistry staining of tissues with 19E3 anti-CAR Ab. (A) Trafficking of targeted T cells to tumor sites in CLL-4 44 hours after T-cell infusion.
  • Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M

  • Blood. 2011 Nov 3;118(18):4817-28.

2012-01-04

Fig 6. Ectopic Neural Folds at the Site of the Absent Foregut Invagination in Early-Somite Stage VE-KO Embryos. (C and D) 3-D reconstructed Z-Stacks of embryos in A and B stained with DAPI (blue) and with antibodies to ECAD(green) and Sox2 (red).

Fig 6. Ectopic Neural Folds at the Site of the Absent Foregut Invagination in Early-Somite Stage VE-KO Embryos. (C and D) 3-D reconstructed Z-Stacks of embryos in A and B stained with DAPI (blue) and with antibodies to ECAD(green) and Sox2 (red).
  • Madabhushi M, Lacy E

  • Dev Cell. 2011 Nov 15;21(5):907-19.

2012-01-05

Fig 1. The wild-type locus. The distribution of nucleosomes before induction, as well as the fractional occupancy of each implied site, is indicated in blue, and the corresponding values following induction are shown in yellow.

Fig 1. The wild-type locus. The distribution of nucleosomes before induction, as well as the fractional occupancy of each implied site, is indicated in blue, and the corresponding values following induction are shown in yellow.
  • Wang X, Bryant GO, Floer M, Spagna D, Ptashne M

  • Nat Struct Mol Biol. 2011 Apr;18(4):507-9.

2012-01-06

Fig 3. LYP: Large pleomorphic and anaplastic tumor cells intermingled with small lymphocytes, eosinophils, and histiocytes (hematoxylin and eosin, original magnification ×200).

Fig 3. LYP: Large pleomorphic and anaplastic tumor cells intermingled with small lymphocytes, eosinophils, and histiocytes (hematoxylin and eosin, original magnification ×200).
  • Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Cerroni L, Berti E, Horwitz S, Prince HM, Guitart J, Estrach T, Sanches JA, Duvic M, Ranki A, Dreno B, Ostheeren-Michaelis S, Knobler R, Wood G, Willemze R

  • Blood. 2011 Oct 13;118(15):4024-35.

2012-01-09

Fig 6. Fluorescence in situ hybridization XY analysis performed on sections from the left forearm biopsy showed that 192 (96%) of 200 cells were XY, or of donor origin, with X and Y chromosomes staining red and green, respectively.

Fig 6. Fluorescence in situ hybridization XY analysis performed on sections from the left forearm biopsy showed that 192 (96%) of 200 cells were XY, or of donor origin, with X and Y chromosomes staining red and green, respectively.
  • Camp BJ, Busam KJ, Brownell I, Koehne G, Hedvat C, Pulitzer MP

  • J Clin Oncol. 2011 Dec 10;29(35):e855-8.

2012-01-10

Fig 1. Progression-free survival.

Fig 1. Progression-free survival.
  • Sierra Del Rio M, Ricard D, Houillier C, Navarro S, Gonzalez-Aguilar A, Idbaih A, Kaloshi G, Elhallani S, Omuro A, Choquet S, Soussain C, Hoang-Xuan K

  • J Neurooncol. 2012 Jan;106(1):143-6.

2012-01-11

Fig 6. Morphology of four HEY1-NCOA2 positive mesenchymal chondrosarcoma cases showing richly cellular fields of small round or slightly spindled cells and islands of chondroid matrix.

Fig 6. Morphology of four HEY1-NCOA2 positive mesenchymal chondrosarcoma cases showing richly cellular fields of small round or slightly spindled cells and islands of chondroid matrix.
  • Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J, Dal Cin P, Antonescu CR, Singer S, Hameed M, Bovee JV, Hogendoorn PC, Socci N, Ladanyi M

  • Genes Chromosomes Cancer. 2012 Feb;51(2):127-39.

2012-01-12

Fig 1b. With polarized dermoscopy (PD), shiny white lines, or crystalline structures (formerly called chrysalislike structures) are visible.

Fig 1b. With polarized dermoscopy (PD), shiny white lines, or crystalline structures (formerly called chrysalislike structures) are visible.
  • Braun RP, Scope A, Marghoob AA

  • Arch Dermatol. 2011 Apr;147(4):520.

2012-01-13

Fig 1b. Infection with enteroinvasive pathogens requires a rapid and robust innate immune response. The presence of microbial products in the lamina propria leads to activation of Toll-like receptor (TLR)-expressing dendritic cells.

Fig 1b. Infection with enteroinvasive pathogens requires a rapid and robust innate immune response. The presence of microbial products in the lamina propria leads to activation of Toll-like receptor (TLR)-expressing dendritic cells.
  • Kinnebrew MA, Pamer EG

  • Immunol Rev. 2012 Jan;245(1):113-31.

2012-01-16

Fig 4. Estimated progression-free survival (PFS) proportion at 1, 2, and 3 years is 0.9, 0.554, and 0.3464, respectively.

Fig 4. Estimated progression-free survival (PFS) proportion at 1, 2, and 3 years is 0.9, 0.554, and 0.3464, respectively.
  • Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H, Pezzulli SD, Sabbatini PJ, Bell-McGuinn KM, Tew WP, Hensley ML, Spriggs DR, Aghajanian CA

  • J Clin Oncol. 2011 Dec 10;29(35):4662-8.

2012-01-17

Figure 1. A Simplified Diagram of the Multiple Endocrine Lineages.

Figure 1. A Simplified Diagram of the Multiple Endocrine Lineages.
  • Tabar V

  • Cell Stem Cell. 2011 Dec 2;9(6):490-1.

2012-01-18

Figure 1. Kaplan–Meier curves demonstrating the probability of freedom from recurrence after PC-RPLND and resection of ERP disease stratified according to RP and ERP histology.

Figure 1. Kaplan–Meier curves demonstrating the probability of freedom from recurrence after PC-RPLND and resection of ERP disease stratified according to RP and ERP histology.
  • Masterson TA, Shayegan B, Carver BS, Bajorin DF, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J

  • Urology. 2012 Jan;79(1):156-9.

2012-01-19

Fig 2. Schema of the current GOG 252 protocol evaluating IP cisplatin vs IP carboplatin and a comparator arm IV-only dose-dense treatment.

Fig 2. Schema of the current GOG 252 protocol evaluating IP cisplatin vs IP carboplatin and a comparator arm IV-only dose-dense treatment.
  • Gardner GJ, Jewell EL

  • Cancer Control. 2011 Jan;18(1):44-51.
Open Access button

2012-01-20

Fig. 5. Papillary tumors on WLI cystoscopy (left), appear dark green on NBI cystoscopy (right), but surrounding brown lesions indicate associated carcinoma in situ.

Fig. 5. Papillary tumors on WLI cystoscopy (left), appear dark green on NBI cystoscopy (right), but surrounding brown lesions indicate associated carcinoma in situ.
  • Herr HH

  • Urol Oncol. 2011 Jul-Aug;29(4):353-7.

2012-01-23

Fig 3. Biallelic BAP1 loss is associated with characteristic histological features in familial melanocytic neoplasms.

Fig 3. Biallelic BAP1 loss is associated with characteristic histological features in familial melanocytic neoplasms.
  • Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rütten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR

  • Nat Genet. 2011 Aug 28;43(10):1018-21.

2012-01-24

Fig 1a. Vemurafenib IC50 curves (at 5 days) for the SKMEL-239 parental cell line and five vemurafenib-resistant clones.

Fig 1a. Vemurafenib IC50 curves (at 5 days) for the SKMEL-239 parental cell line and five vemurafenib-resistant clones.
  • Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB

  • Nature. 2011 Nov 23;480(7377):387-90.

2012-01-25

Fig 1. Schematic representation of PKCδ/retinol signalosome.

Fig 1. Schematic representation of PKCδ/retinol signalosome.
  • Hoyos B, Acin-Perez R, Fischman DA, Manfredi G, Hammerling U

  • Biochim Biophys Acta. 2012 Jan;1821(1):241-7.

2012-01-26

Fig 6. AdVance sling.

Fig 6. AdVance sling.
  • Bauer RM, Gozzi C, Hübner W, Nitti VW, Novara G, Peterson A, Sandhu JS, Stief CG

  • Eur Urol. 2011 Jun;59(6):985-96.

2012-01-27

Fig 5b. HEY1-NCOA2 dual-color FISH pictures. Fused signals (visible as one yellow dot, instead of green dot/red dot side by side) were seen in cells of RT-PCR positive cases MSK_3 and MSK_6.

Fig 5b. HEY1-NCOA2 dual-color FISH pictures. Fused signals (visible as one yellow dot, instead of green dot/red dot side by side) were seen in cells of RT-PCR positive cases MSK_3 and MSK_6.
  • Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J, Dal Cin P, Antonescu CR, Singer S, Hameed M, Bovee JV, Hogendoorn PC, Socci N, Ladanyi M

  • Genes Chromosomes Cancer. 2012 Feb;51(2):127-39.

2012-01-30

Fig 2. (18F) 2-fluoro-2-deoxyglucose-positron emission tomography/computed tomography detects diffuse bony metastases not seen on staging computed tomography.

Fig 2. (18F) 2-fluoro-2-deoxyglucose-positron emission tomography/computed tomography detects diffuse bony metastases not seen on staging computed tomography.
  • Smyth EC, Shah MA

  • World J Gastroenterol. 2011 Dec 14;17(46):5059-74.
Open Access button

2012-01-31

Fig 10. Chemical stability of the RtcB-[32P]guanylate adduct.

Fig 10. Chemical stability of the RtcB-[32P]guanylate adduct.
  • Tanaka N, Chakravarty AK, Maughan B, Shuman S

  • J Biol Chem. 2011 Dec 16;286(50):43134-43.

2012-02-01

Fig 2. Predicted 3D structure for ELAV4 human protein.

Fig 2. Predicted 3D structure for ELAV4 human protein.
  • Marks DS, Colwell LJ, Sheridan R, Hopf TA, Pagnani A, Zecchina R, Sander C

  • PLoS One. 2011;6(12):e28766.
Open Access button

2012-02-02

Fig 5a. Model for RARα dependent epigenetic regulation.

Fig 5a. Model for RARα dependent epigenetic regulation.
  • Laursen KB, Wong PM, Gudas LJ

  • Nucleic Acids Res. 2012 Jan;40(1):102-15.
Open Access button

2012-02-03

Fig 1. Clinical features and radiographs of affected individuals from families AO39 and AO70 and subject 248412 showing brachydactyly, brachymesophalangy of the second and fifth fingers (better appreciated on the palmar view, arrows), hypoplastic thumbs of variable severity (asterisks) and cutaneous syndactyly of toes (arrow heads).

Fig 1. Clinical features and radiographs of affected individuals from families AO39 and AO70 and subject 248412 showing brachydactyly, brachymesophalangy of the second and fifth fingers (better appreciated on the palmar view, arrows), hypoplastic thumbs of variable severity (asterisks) and cutaneous syndactyly of toes (arrow heads).
  • de Pontual L, Yao E, Callier P, Faivre L, Drouin V, Cariou S, Van Haeringen A, Geneviève D, Goldenberg A, Oufadem M, Manouvrier S, Munnich A, Vidigal JA, Vekemans M, Lyonnet S, Henrion-Caude A, Ventura A, Amiel J

  • Nat Genet. 2011 Sep 4;43(10):1026-30.

2012-02-06

Fig 1. Illustrative case from La Starza et al. where interphase FISH was used to understand the clonal hierarchy and clinical correlates in TET2 altered myeloid malignancy.

Fig 1. Illustrative case from La Starza et al. where interphase FISH was used to understand the clonal hierarchy and clinical correlates in TET2 altered myeloid malignancy.
  • Pignataro DS, Abdel-Wahab O

  • Leuk Res. 2012 Jan;36(1):25-6.

2012-02-07

Fig 1. Schematic representation of PKCδ/retinol signalosome.

Fig 1. Schematic representation of PKCδ/retinol signalosome.
  • Hoyos B, Acin-Perez R, Fischman DA, Manfredi G, Hammerling U

  • Biochim Biophys Acta. 2012 Jan;1821(1):241-7.

2012-02-08

Fig 1. Probability of missing nodal disease as a function of nodes examined in 4335 patients who were treated with radical cystectomy with pelvic lymphadenectomy.

Fig 1. Probability of missing nodal disease as a function of nodes examined in 4335 patients who were treated with radical cystectomy with pelvic lymphadenectomy.
  • Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JI, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, Scherr DS, Gonen M

  • Eur Urol. 2012 Feb;61(2):237-42.

2012-02-09

Fig 3. Rac1 mutant mesoderm cells fail to migrate.

Fig 3. Rac1 mutant mesoderm cells fail to migrate.
  • Migeotte I, Grego-Bessa J, Anderson KV

  • Development. 2011 Jul;138(14):3011-20.

2012-02-10

Graphical Abstract

Graphical Abstract
  • Chen Q, Zhang XH, Massagué J

  • Cancer Cell. 2011 Oct 18;20(4):538-49.

2012-02-13

Fig 1. Kaplan-Meier OS rate and cumulative incidence of LF, RF, and DM. Abbreviations: LF = local failure; RF = regional failure; DM = distant metastasis; LFFS = local failure-free survival; RFFS = regional failure-free survival; DMFS = distant metastasis-free survival.

Fig 1. Kaplan-Meier OS rate and cumulative incidence of LF, RF, and DM. Abbreviations: LF = local failure; RF = regional failure; DM = distant metastasis; LFFS = local failure-free survival; RFFS = regional failure-free survival; DMFS = distant metastasis-free survival.
  • Setton J, Caria N, Romanyshyn J, Koutcher L, Wolden SL, Zelefsky MJ, Rowan N, Sherman EJ, Fury MG, Pfister DG, Wong RJ, Shah JP, Kraus DH, Shi W, Zhang Z, Schupak KD, Gelblum DY, Rao SD, Lee NY

  • Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):291-8.

2012-02-14

Fig 2b. Overall survival (OS) by residual disease of patients undergoing primary debulking surgery from 9/98–12/06.

Fig 2b. Overall survival (OS) by residual disease of patients undergoing primary debulking surgery from 9/98–12/06.
  • Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR

  • Gynecol Oncol. 2012 Jan;124(1):10-4.

2012-02-15

Fig 4. The MRE11 complex in human disease and mouse models. (b) The MRE11 complex has multiple roles in activating apoptosis after double-strand break (DSB) exposure.

Fig 4. The MRE11 complex in human disease and mouse models. (b) The MRE11 complex has multiple roles in activating apoptosis after double-strand break (DSB) exposure.
  • Stracker TH, Petrini JH

  • Nat Rev Mol Cell Biol. 2011 Feb;12(2):90-103.

2012-02-16

Fig 1. Morphological appearance of epithelioid vascular tumors analyzed in this study.

Fig 1. Morphological appearance of epithelioid vascular tumors analyzed in this study.
  • Errani C, Zhang L, Sung YS, Hajdu M, Singer S, Maki RG, Healey JH, Antonescu CR

  • Genes Chromosomes Cancer. 2011 Aug;50(8):644-53.

2012-02-17

Fig 3. Relative frequency of driver mutations in patients with lung adenocarcinoma. Driver mutations can now been identified in the majority of patients with lung adenocarcinoma.

Fig 3. Relative frequency of driver mutations in patients with lung adenocarcinoma. Driver mutations can now been identified in the majority of patients with lung adenocarcinoma.
  • Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ

  • J Clin Oncol. 2011 May 20;29(15):2046-51.

2012-02-20

Fig. 3A. Communication between lipid droplets. (A) 3T3-L1 adipocytes were pulse-labeled with 5 μM BODIPY-C16 for 20 s, rinsed and chased without label for an additional 60 min.

Fig. 3A. Communication between lipid droplets. (A) 3T3-L1 adipocytes were pulse-labeled with 5 μM BODIPY-C16 for 20 s, rinsed and chased without label for an additional 60 min.
  • Somwar R, Roberts CT Jr, Varlamov O

  • FEBS Lett. 2011 Jun 23;585(12):1946-50.

2012-02-21

Fig 10. Chemical stability of the RtcB-[32P]guanylate adduct.

Fig 10. Chemical stability of the RtcB-[32P]guanylate adduct.
  • Tanaka N, Chakravarty AK, Maughan B, Shuman S

  • J Biol Chem. 2011 Dec 16;286(50):43134-43.

2012-02-22

Fig 1. Nonviable tumor was defined as tumor showing signs of irreversible cell injury such as karyolysis (A) and karyorrhexis (B).

Fig 1. Nonviable tumor was defined as tumor showing signs of irreversible cell injury such as karyolysis (A) and karyorrhexis (B).
  • Ganly I, Bocker J, Carlson DL, D'Arpa S, Coleman M, Lee N, Pfister DG, Shah JP, Patel SG

  • Head Neck. 2011 Oct;33(10):1387-93.

2012-02-23

Fig 1. Overall survival according to sex in the Childhood Cancer Survivor Study cohort and expected survival based on age-, year-, and sex-matched US population mortality rates are shown.

Fig 1. Overall survival according to sex in the Childhood Cancer Survivor Study cohort and expected survival based on age-, year-, and sex-matched US population mortality rates are shown.
  • Oeffinger KC, Tonorezos ES

  • Cancer. 2011 May 15;117(10 Suppl):2250-7.

2012-02-24

Fig 1. Percentage of patients undergoing unilateral mastectomy without reconstruction on a 1-day hospitalization basis from January 2009 to June 2010.

Fig 1. Percentage of patients undergoing unilateral mastectomy without reconstruction on a 1-day hospitalization basis from January 2009 to June 2010.
  • Weber WP, Barry M, Junqueira MJ, Lee SS, Mazzella AM, Sclafani LM

  • Eur J Surg Oncol. 2011 Nov;37(11):944-9.

2012-02-27

Fig 2. Heat map looking at differential changes of common genes. For this case each gene is normalized as a mean expression of zero. Blue shows samples with expression below mean and red is expression above mean.

Fig 2. Heat map looking at differential changes of common genes. For this case each gene is normalized as a mean expression of zero. Blue shows samples with expression below mean and red is expression above mean.
  • Song TJ, Haddad D, Adusumilli P, Kim T, Stiles B, Hezel M, Socci ND, Gönen M, Fong Y

  • Cancer Gene Ther. 2012 Jan;19(1):38-48.

2012-02-28

Fig 1a. Blue solid line indicates low predicted risk (PSAR PX model score ≤ 41); red dashed line indicates high predicted risk (PSAR PX model score > 41).

Fig 1a. Blue solid line indicates low predicted risk (PSAR PX model score ≤ 41); red dashed line indicates high predicted risk (PSAR PX model score > 41).
  • Donovan MJ, Khan FM, Powell D, Bayer-Zubek V, Cordon-Cardo C, Costa J, Eastham J, Scardino P

  • BJU Int. 2012 Jan;109(1):40-5.

2012-02-29

Fig 1. Models of combinatorial readout of two histone marks by paired chromatin-associated modules.

Fig 1. Models of combinatorial readout of two histone marks by paired chromatin-associated modules.
  • Wang Z, Patel DJ

  • J Biol Chem. 2011 May 27;286(21):18363-8.

2012-03-01

Fig 2. Factors associated with breast cancer patients’ decision about postmastectomy breast reconstruction.

Fig 2. Factors associated with breast cancer patients’ decision about postmastectomy breast reconstruction.
  • Alderman AK, Hawley ST, Morrow M, Salem B, Hamilton A, Graff JJ, Katz S

  • Ann Surg Oncol. 2011 Jun;18(6):1748-56

2012-03-02

Fig 1a. Predicted secondary structure of w-miR and its predicted interaction with the target sequence in the white 3′ UTR. The predicted mature strand is indicated in red.

Fig 1a. Predicted secondary structure of w-miR and its predicted interaction with the target sequence in the white 3′ UTR. The predicted mature strand is indicated in red.
  • Smibert P, Bejarano F, Wang D, Garaulet DL, Yang JS, Martin R, Bortolamiol-Becet D, Robine N, Hiesinger PR, Lai EC

  • RNA. 2011 Nov;17(11):1997-2010.

2012-03-05

Fig 1. Schematic of workflow. Modifications to a previously reported TK screening platform were incorporated to take advantage of short-read paired-end sequencing using an ABI SOLiD sequencer.

Fig 1. Schematic of workflow. Modifications to a previously reported TK screening platform were incorporated to take advantage of short-read paired-end sequencing using an ABI SOLiD sequencer.
  • Chmielecki J, Peifer M, Viale A, Hutchinson K, Giltnane J, Socci ND, Hollis CJ, Dean RS, Yenamandra A, Jagasia M, Kim AS, Davé UP, Thomas RK, Pao W

  • Genes Chromosomes Cancer. 2012 Jan;51(1):54-65.

2012-03-06

Fig 1b. Examination of the mode of cell-death following ADPM06-PDT. Percentages of cell populations in early apoptosis, late apoptosis and necrosis are shown.

Fig 1b. Examination of the mode of cell-death following ADPM06-PDT. Percentages of cell populations in early apoptosis, late apoptosis and necrosis are shown.
  • O'Connor AE, Mc Gee MM, Likar Y, Ponomarev V, Callanan JJ, O'shea DF, Byrne AT, Gallagher WM

  • Int J Cancer. 2012 Feb 1;130(3):705-15.

2012-03-07

Fig 1. Preoperative ultrasound revealing a hypoechoic periportal mass and intrahepatic biliary dilatation.

Fig 1. Preoperative ultrasound revealing a hypoechoic periportal mass and intrahepatic biliary dilatation.
  • Panait L, Learn P, Dimaio C, Klimstra D, Do KG, Schwarz T, D'Angelica M, Dematteo R, Kingham P, Allen P, Fong Y, Jarnagin WR

  • Surg Oncol. 2011 Dec;20(4):e157-9.

2012-03-08

Fig 1. Promoter and terminator combinations to drive spore-autonomous expression of fluorescent proteins.

Fig 1. Promoter and terminator combinations to drive spore-autonomous expression of fluorescent proteins.
  • Thacker D, Lam I, Knop M, Keeney S

  • Genetics. 2011 Oct;189(2):423-39.

2012-03-09

Fig 3(a). β-globin expression in the erythroid progeny of single-vector-copy thal-iPS cell clones. Expression of erythroid cell markers CD71 and glycophorin A (GPA) in the erythroid progeny of thal-iPS cell line 1.52.

Fig 3(a). β-globin expression in the erythroid progeny of single-vector-copy thal-iPS cell clones. Expression of erythroid cell markers CD71 and glycophorin A (GPA) in the erythroid progeny of thal-iPS cell line 1.52.
  • Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman FD, Studer L, Sadelain M

  • Nat Biotechnol. 2011 Jan;29(1):73-8.

2012-03-12

Fig 8. TCR-induced cytokine production requires PKC-θ, PKC-ε and PKC-η.

Fig 8. TCR-induced cytokine production requires PKC-θ, PKC-ε and PKC-η.
  • Quann EJ, Liu X, Altan-Bonnet G, Huse M

  • Nat Immunol. 2011 May 22;12(7):647-54.

2012-03-13

Fig 1a. Interaction network of C/EBPα and PPARγ derived from Ingenuity pathway analysis.

Fig 1a. Interaction network of C/EBPα and PPARγ derived from Ingenuity pathway analysis.
  • Wu YV, Okada T, Decarolis P, Socci N, O'Connor R, Geha RC, Joy Somberg C, Antonescu C, Singer S

  • Genes Chromosomes Cancer. 2012 Apr;51(4):313-27.

2012-03-14

Supplemental Fig 1. Uterine leiomyosarcoma (A) showing 3 + expression for PR (B).

Supplemental Fig 1. Uterine leiomyosarcoma (A) showing 3 + expression for PR (B).
  • Leitao MM Jr, Hensley ML, Barakat RR, Aghajanian C, Gardner GJ, Jewell EL, O'Cearbhaill R, Soslow RA

  • Gynecol Oncol. 2012 Mar;124(3):558-62.

2012-03-15

Fig 1. Frontier analysis of cost-effectiveness.

Fig 1. Frontier analysis of cost-effectiveness.
  • Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Gareen IF, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, Johnson CD

  • Radiology. 2011 Nov;261(2):487-498.

2012-03-16

Fig. 7 Results of measurements of the spatial resolution (ie, the PSF) of a gamma probe.

Fig. 7 Results of measurements of the spatial resolution (ie, the PSF) of a gamma probe.
  • Heller S, Zanzonico P

  • Semin Nucl Med. 2011 May;41(3):166-81.

2012-03-19

Fig 1. A biopsy sample of a colonic adenocarcinoma showing focal and weak staining for MLH1 (A). This tumor showed complete loss of staining for PMS2 (B), and retained staining for MSH2 (C) and MSH6 (D) in both biopsy and resection (pictures shown are all from biopsy samples), and the patient had a pathogenic mutation in MLH1.

Fig 1. A biopsy sample of a colonic adenocarcinoma showing focal and weak staining for MLH1 (A). This tumor showed complete loss of staining for PMS2 (B), and retained staining for MSH2 (C) and MSH6 (D) in both biopsy and resection (pictures shown are all from biopsy samples), and the patient had a pathogenic mutation in MLH1.
  • Shia J, Stadler Z, Weiser MR, Rentz M, Gonen M, Tang LH, Vakiani E, Katabi N, Xiong X, Markowitz AJ, Shike M, Guillem J, Klimstra DS

  • Am J Surg Pathol. 2011 Mar;35(3):447-54.

2012-03-20

Fig 1a. The majority if EPRs were long-stem cemented hemiarthroplasties.

Fig 1a. The majority if EPRs were long-stem cemented hemiarthroplasties.
  • Steensma M, Boland PJ, Morris CD, Athanasian E, Healey JH

  • Clin Orthop Relat Res. 2012 Mar;470(3):920-6.

2012-03-21

Fig 1. Kinase inhibition leads to adenosine triphosphate depletion in the mitochondrion-rich myocyte.

Fig 1. Kinase inhibition leads to adenosine triphosphate depletion in the mitochondrion-rich myocyte.
  • Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, Leier CV, Liu G, Lenihan D, Lindenfeld J, Maitland ML, Remick SC, Tang WH

  • Am Heart J. 2012 Feb;163(2):156-63.

2012-03-22

Fig 3. Oncogenic mutations identified in ERMS samples. Mutations in one of 6 known cancer genes were identified in approximately 28% of all ERMS samples tested.

Fig 3. Oncogenic mutations identified in ERMS samples. Mutations in one of 6 known cancer genes were identified in approximately 28% of all ERMS samples tested.
  • Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A, Borsu L, Barr FG, Ladanyi M

  • Clin Cancer Res. 2012 Feb 1;18(3):748-57.

2012-03-23

Fig 8. HMGB1 blockade attenuates inflammatory lymphangiogenesis in draining lymph nodes.

Fig 8. HMGB1 blockade attenuates inflammatory lymphangiogenesis in draining lymph nodes.
  • Zampell JC, Yan A, Avraham T, Andrade V, Malliaris S, Aschen S, Rockson SG, Mehrara BJ

  • Am J Physiol Cell Physiol. 2011 May;300(5):C1107-21.

2012-03-26

Fig 1a. Model of extracellular signal–regulated kinase (ERK) activation by RAF inhibitors in RAS mutant tumors.

Fig 1a. Model of extracellular signal–regulated kinase (ERK) activation by RAF inhibitors in RAS mutant tumors.
  • Lacouture ME, O'Reilly K, Rosen N, Solit DB

  • J Clin Oncol. 2012 Jan 20;30(3):329-30.

2012-03-27

Fig 1. Left endosellar human growth hormone microadenoma demonstrated on T1-weighted contrast-enhanced 3D MPRAGE 3-tesla (left) and standard 1.5-tesla (right) MR images.

Fig 1. Left endosellar human growth hormone microadenoma demonstrated on T1-weighted contrast-enhanced 3D MPRAGE 3-tesla (left) and standard 1.5-tesla (right) MR images.
  • Wolfsberger S, Ba-Ssalamah A, Pinker K, Mlynárik V, Czech T, Knosp E, Trattnig S

  • J Neurosurg. 2004 Feb;100(2):278-86.

2012-03-28

Fig 4. Distribution of gene expression per copy number variation from ovarian cancer tumor cells.

Fig 4. Distribution of gene expression per copy number variation from ovarian cancer tumor cells.
  • Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, Levine DA, Dimitrova N, Zhang MQ, Lucito R

  • PLoS One. 2011;6(12):e28503.
Open Access button

2012-03-29

Fig 2. Large polygonal cells with well-defined cell borders and granular basophilic cytoplasm (Papanicolaou, ×100).

Fig 2. Large polygonal cells with well-defined cell borders and granular basophilic cytoplasm (Papanicolaou, ×100).
  • Sigel CS, Park KJ, Fine SW, Lin O

  • Diagn Cytopathol. 2012 Feb;40(2):168-72.

2012-03-30

Fig 1c. Assessment of pluripotent and somatic cell samples in the training dataset with the pluripotency score.

Fig 1c. Assessment of pluripotent and somatic cell samples in the training dataset with the pluripotency score.
  • Müller FJ, Schuldt BM, Williams R, Mason D, Altun G, Papapetrou EP, Danner S, Goldmann JE, Herbst A, Schmidt NO, Aldenhoff JB, Laurent LC, Loring JF

  • Nat Methods. 2011 Apr;8(4):315-7.